The Low Density Lipoprotein Receptor Related Protein 6 pipeline drugs market research report outlays comprehensive information on the Low Density Lipoprotein Receptor Related Protein 6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Low Density Lipoprotein Receptor Related Protein 6 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Respiratory, Ophthalmology, and Musculoskeletal Disorders which include the indications Ulcerative Colitis, Crohn’s Disease (Regional Enteritis), Idiopathic Pulmonary Fibrosis, Lung Disease, Diabetic Retinopathy, Age Related Macular Degeneration, and Bone Disorders. It also reviews key players involved in Low Density Lipoprotein Receptor Related Protein 6 targeted therapeutics development with respective active and dormant or discontinued products.
The Low Density Lipoprotein Receptor Related Protein 6 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 1, and 3 respectively.
Low Density Lipoprotein Receptor Related Protein 6 overview
Low-density lipoprotein receptor-related protein 6 is a protein that in humans is encoded by the LRP6 gene. LDL receptors are transmembrane cell surface proteins involved in receptor-mediated endocytosis of lipoprotein and protein ligands. The protein encoded by this gene functions as a receptor or, with Frizzled, a co-receptor for Wnt and thereby transmits the canonical Wnt/beta-catenin signaling cascade. Through its interaction with the Wnt/beta-catenin signaling cascade this gene plays a role in the regulation of cell differentiation, proliferation, and migration and the development of many cancer types.
For a complete picture of Low Density Lipoprotein Receptor Related Protein 6’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
